{"id":7047716,"date":"2026-08-25T19:49:32","date_gmt":"2026-08-25T19:49:32","guid":{"rendered":"https:\/\/peraltafinancing.com\/business\/legal\/fda-addresses-device-constituents-in-new-draft-guidance-on-container-closure-systems\/"},"modified":"2026-08-25T19:49:32","modified_gmt":"2026-08-25T19:49:32","slug":"fda-addresses-device-constituents-in-new-draft-guidance-on-container-closure-systems","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=7047716","title":{"rendered":"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems"},"content":{"rendered":"


\n<\/p>\n

\n

FDA recently released a draft guidance titled Container Closure Systems for Human Drugs and Biological Products<\/a>. The draft supersedes a 1999 guidance and its 2002 Q&A supplement\u2014documents written before the prevalence of container closure systems (CCSs) like pre-filled syringes, metered dose inhalers, and autoinjectors blurred the line between container and device.\u00a0 For Combination Product manufacturers, the new draft now explicitly acknowledges that a CCS may also be a device constituent or part of a device constituent and mentions, although with no specificity, that some recommendations may also be applicable to stand-alone drug-delivery devices.\u00a0 However, the headline is that the draft guidance does not appear to introduce anything that has not already been covered in another guidance related to combination products.<\/p>\n

The draft guidance organizes CCS evaluation around a risk-based framework covering safety of packaging materials, protection, performance, manufacturing process impacts, and storage.\u00a0 It further provides recommendations for quality assessment and control, including an evaluation of protection; safety and compatibility, which includes extractables and leachables (E&L) assessments and nonclinical toxicological risk assessments; performance; stability; and tests for shipping, handling, and storage. \u00a0The draft guidance emphasizes that evaluation of a CCS is product-specific and that a CCS that is suitable for one drug product may not be an appropriate choice for another.\u00a0 This is especially important for combination product sponsors to keep in mind when selecting a device constituent CCS.\u00a0 Additional evaluation specific to the use of that device constituent CCS will be necessary to evaluate risk and conduct appropriate quality assessments beyond that which the developer of the device constituent has conducted.<\/p>\n

As required by 21 C.F.R. Part 4, CCSs that are device constituent parts must comply with ISO 13485:2016 Clauses 7.3 (design and development) and 7.4 (purchasing), per 21 C.F.R. 820.10(c). The draft guidance also notes that Part 820 exemptions may not survive integration into a CCS.\u00a0 As an example, \u00a0a dropper on its own might be exempt, but the same dropper built into a bottle cap would have a new use as part of the container closure and no longer be exempt.<\/p>\n

For a CCS that is also a device constituent part, FDA expects appropriate testing to demonstrate the device\u2019s function, delivery performance, and usability, consistent with other guidance, including for Essential Drug Delivery Outputs (see prior post here<\/a>) and Human Factors.<\/p>\n

The draft guidance also devotes significant attention to E&L and nonclinical toxicological risk assessments, including safety concern thresholds, qualification thresholds, and analytical evaluation thresholds. Notably, FDA recommends that for combination products, \u201cthe risk and extent and adequacy of testing should also take into account whether interactions between a CCS that is a device constituent part and the drug or biological product constituent part it holds (such as adsorption of the drug or biological product constituent part by the CCS) might negatively affect device performance.\u201d This is a critical nuance: An E&L program needs to account not just for patient safety from leachables but also for the impact of drug-device interactions on the device\u2019s ability to deliver the drug as labeled.<\/p>\n

FDA also signals that more is coming. The guidance notes that FDA intends to issue additional topic-specific guidance, addressing methods for evaluating novel CCSs and providing information about specific quality attributes and testing requirements, including E&L evaluations and toxicological risk assessments. The pending ICH Q3E guideline on E&L assessments is also referenced.<\/p>\n

FDA\u2019s draft guidance on container closure systems represents an update that consolidates nearly three decades of regulatory evolution into its framework. For combination product sponsors, the guidance does not appear to break significant new ground beyond what existing combination product guidances already address, but it does place relevant threads\u2014CCS quality assessment, device constituent part requirements, extractables and leachables evaluation, and design control obligations\u2014under one roof. The explicit acknowledgment that a CCS may also function as a device constituent part, and the corresponding expectation that E&L programs account for drug-device interactions affecting device performance, warrant close attention during program design.<\/p>\n

Affected parties should prioritize submitting comments before the deadline on October 13, 2026, conduct internal gap assessments, and monitor for the forthcoming topic-specific supplemental guidance documents.<\/p>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"

FDA recently released a draft guidance titled Container Closure Systems for Human Drugs and Biological Products. The draft supersedes a 1999 guidance and its 2002 Q&A supplement\u2014documents written before the prevalence of container closure systems (CCSs) like pre-filled syringes, metered dose inhalers, and autoinjectors blurred the line between container and device.\u00a0 For Combination Product manufacturers, […]<\/p>\n","protected":false},"author":1,"featured_media":354832,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[97],"tags":[35364,5135,42894,1498,15313,15878,19889,13319,11355],"dealstore":[],"offerexpiration":[],"class_list":["post-7047716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-legal","tag-addresses","tag-closure","tag-constituents","tag-container","tag-device","tag-draft","tag-fda","tag-guidance","tag-systems"],"yoast_head":"\nFDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=7047716\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"FDA recently released a draft guidance titled Container Closure Systems for Human Drugs and Biological Products. The draft supersedes a 1999 guidance and its 2002 Q&A supplement\u2014documents written before the prevalence of container closure systems (CCSs) like pre-filled syringes, metered dose inhalers, and autoinjectors blurred the line between container and device.\u00a0 For Combination Product manufacturers, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=7047716\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-25T19:49:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=7047716#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=7047716\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems\",\"datePublished\":\"2026-08-25T19:49:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=7047716\"},\"wordCount\":708,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=7047716#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg\",\"keywords\":[\"addresses\",\"Closure\",\"constituents\",\"Container\",\"Device\",\"Draft\",\"FDA\",\"Guidance\",\"Systems\"],\"articleSection\":[\"Legal\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=7047716#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=7047716\",\"url\":\"https:\/\/fivemor.com\/?p=7047716\",\"name\":\"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=7047716#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=7047716#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg\",\"datePublished\":\"2026-08-25T19:49:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=7047716#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=7047716\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/?p=7047716#primaryimage\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=7047716#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=7047716","og_locale":"en_US","og_type":"article","og_title":"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems - Som2ny Network","og_description":"FDA recently released a draft guidance titled Container Closure Systems for Human Drugs and Biological Products. The draft supersedes a 1999 guidance and its 2002 Q&A supplement\u2014documents written before the prevalence of container closure systems (CCSs) like pre-filled syringes, metered dose inhalers, and autoinjectors blurred the line between container and device.\u00a0 For Combination Product manufacturers, […]","og_url":"https:\/\/fivemor.com\/?p=7047716","og_site_name":"Som2ny Network","article_published_time":"2026-08-25T19:49:32+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=7047716#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=7047716"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems","datePublished":"2026-08-25T19:49:32+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=7047716"},"wordCount":708,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"image":{"@id":"https:\/\/fivemor.com\/?p=7047716#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg","keywords":["addresses","Closure","constituents","Container","Device","Draft","FDA","Guidance","Systems"],"articleSection":["Legal"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=7047716#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=7047716","url":"https:\/\/fivemor.com\/?p=7047716","name":"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fivemor.com\/?p=7047716#primaryimage"},"image":{"@id":"https:\/\/fivemor.com\/?p=7047716#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg","datePublished":"2026-08-25T19:49:32+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=7047716#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=7047716"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/?p=7047716#primaryimage","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/1783503367_blank.jpg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=7047716#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"FDA Addresses Device Constituents in New Draft Guidance on Container Closure Systems"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/7047716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7047716"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/7047716\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/media\/354832"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7047716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7047716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7047716"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=7047716"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=7047716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}